



Burnet
reach for the many

Commercial-ready: discovery to delivery

Burnet has the research experience
and commercial acumen to bring
your innovation to market.



Independent. International. Pragmatic.

Why we're different to other research institutes



We are more flexible and agile than university- or government-based institutes.



We work across Asia Pacific and collaborate on projects in other continents.



Our technical skills base spans laboratory research right through to implementation and clinical applications.

Unmatched breadth of research

Life Sciences

Public Health

International Development



Our point of difference is our ability to provide end-to-end solutions to global health challenges using multidisciplinary teams across discovery science, public health and international development.

Proven commercial track record

360biolabs

Burnet's business, 360biolabs, became Australia's most diverse bioanalytical and specialty laboratory offering science-driven expertise and laboratory services for therapeutic, vaccine and diagnostic development. This, combined with its globally recognised team, culminated in the sale to biotech organisation BioAgilityx.

2015	Co-founded by Burnet Institute in Melbourne, Australia
2021	Acquired by BioAgilityx for AUD \$282 million

Burnet Diagnostics Initiative (BDI)

Our ISO 9001-certified group produces commercially viable, accurate and low-cost products for unmet health needs:

- developed the WHO-endorsed VISITECT® CD4, the first equipment-free point of care test to monitor HIV disease progression
- licensed multiple diagnostic assays in international markets – hepatitis E, CD4 HIV, syphilis
- offers a fee-for-service diagnostic research, development work and customisation services.

Burnnext accelerator program

Our Burnnext model fast-tracks translational research by removing funding barriers, which often inhibit researchers developing ideas into real-world outcomes. It takes projects from proof-of-concept to an intense process of milestone-driven project planning and delivery stages, to ensure outcomes within 24 months.

Through Burnnext, we are also able to co-invest with potential partners.

Burnet Institute has invested an initial **AUD \$6.5 million** in Burnnext.



ISO 9001 certified

BDI achieved ISO 9001 Certification in 2023 based on the highest international quality standards including a strong client focus, the process approach and a commitment to continual improvement.

All Burnet research translation activities now have access to the ISO 9001 quality management system. This means we are industry-ready and our collaborators are confident that we conduct our research in an ethical, robust and reproducible way.



End-to-end capability

For nearly 40 years, Burnet has worked to address the most pressing global health challenges and ensure no-one is left behind. From lab bench to field, our multidisciplinary approach is backed by experts in:

- Discovery and translation
- Clinical trials and cohort studies
- Biomedical research
- Public health research
- Epidemiology
- Health systems strengthening
- Data analytics and modelling
- Implementation science
- Community engagement and co-design
- International development

550+

staff in research, public health and support services.

30m+

Endorsed by WHO, the quick and affordable VISITECT CD4 diagnostic tool enables better care for more than 30 million people who live with **HIV** in low-income countries.

70+


We have worked with more than 70 countries to deliver **modelling analyses** that informed health policy or investment decisions.

100

Burnet works closely with **governments and communities in Papua New Guinea (PNG)**, with a team of 100-plus researchers and public health professionals supporting projects in many provinces.



Led by Burnet, EC Australia has reduced rates of **hepatitis C** by 50%. We're now halfway to our elimination goal, and we're sharing our expertise with the world.



We helped local teams stabilise the **tuberculosis emergency** in Western Province in PNG. Treatment success rates increased from 50% in 2013 to over 80% from 2016 onwards.

04

offices in Australia and Asia-Pacific.

10

 We've worked on **malaria elimination** with teams in 10 countries: PNG, Myanmar, Laos, Cambodia, Vietnam, Thailand, Indonesia, Kenya, Malawi, and Uganda.

International track record and impact

Burnet is the only medical research institute that is fully accredited by the Australian Government as a non-government organisation. This enables us to work with communities and take discoveries to real-world settings to improve health equity.

We have offices in Papua New Guinea, Myanmar and Vanuatu, and contribute to research and public health programs in other countries across Asia, the Pacific, Africa, Europe, and North America.



Clockwise from top: a grandmother and her granddaughter attend a maternal health clinic in Erakor, Vanuatu, with Burnet research coordinator, Kali Ameara. Our mobile tuberculosis clinic in Papua New Guinea aims to reduce transmission in communities through early detection, treatment, and counselling. Professor Joe Doyle, Burnet researcher and infectious disease specialist, chats with a pharmacist about Expand-C, a Burnet project aiming to reach people at risk of hepatitis C.

Global leaders in science translation

Research translation and commercialisation



**Jen Barnes, Director, Commercialisation and Research Translation;
Director, Burnet Diagnostics Initiative**

Seasoned commercialisation executive with over 20 years' success working with scientists to translate research into market-ready health solutions. Brings a diverse background across science, marketing, sales, strategy, and business development, with a focus on diagnostics and medical devices. Experienced in large multinationals, as a start-up founder and CEO, and in executive leadership within the medical research sector.



Professor Heidi Drummer, Scientific Director for Research Translation

Scientific Director of the Burnet Diagnostics Initiative and co-head of the Viral Entry and Vaccines research group. Internationally recognised as a leader in translational science and viral hepatitis with 30 years' experience in the development of diagnostics, vaccines and therapeutics, and commercialisation of diagnostic assays.



Carli Roulston, Senior Manager, Business Development

Over 25 years' experience in medicine and medical device development. Extensive experience in attracting funding, investment and partnerships to research. Former Head of Commercialisation at The Florey Institute. PhD in Pharmacology from Monash University.



Geoff Drenkhahn, Chief, Funding Growth

Over 30 years' experience in R+D sector, including 8 years as the inaugural Chief Operating Officer at Burnet Institute. Instrumental role in the growth of Burnet including identifying alternative funding avenues such as the commercialising of Burnet technologies and the establishment and eventual sale of 360biolabs. Holds MBA in Technology Management, and completed leadership programs at MIT and Harvard Business School.

Board



Ms Mary Padbury BA, LLB (Hons), Chair since 2019, Director since 2011

Four-decade legal career specialising in intellectual property law. Commonwealth Bank of Australia director, Australian Brandenburg Orchestra director, Richmond Football Club Limited Custodian director and Ormond College director at The University of Melbourne.



Professor Brendan Crabb AC PhD FAA FAHMS FASM, Director and CEO since 2008

Leading Australian scientist and infectious disease researcher. Served on governing council of Australian National Health and Medical Research Council from 2016-2021. President of Australian Global Health Alliance and Pacific Friends of Global Health. Member of the International Advisory Board of the Sanger Institute (UK), and the WHO Malaria Vaccine Advisory Committee. Chair, Australian Academy of Science sectional committee on Molecular and Cell Biology, and Human Genetics.



Dr Andrew Nash, Director since 2025

Former Chief Scientific Officer and Senior Vice-President (Research) at CSL Limited. Former CEO of Zenyth Therapeutics. Extensive immunology and biotechnology experience, PhD in Immunology. Fellow of Australian Academy of Technological Sciences and Engineering since 2021.

Current partnering opportunities

Stellabody®

- transformative technology that improves the efficacy of cancer, inflammation and infectious disease treatments
- can deliver up to 100 times more potent action than standard antibody therapeutics

Diagnostics

- point of care test for liver function
- active syphilis diagnosis
- diagnostic assay for measurement of dimeric IgA
- diagnostic development service facility

Vaccines

- platform technology for development of stable coronavirus vaccines including MERS
- malaria

Ageing and inflammation


- biomarkers
- ageing B-cells

Microbiome

- gel for optimal vaginal microbiome
- model for vaginal-microbiome host interactions

Public and international health

- technical expertise to support and strengthen health systems
- responses to health challenges in the Asia-Pacific region
- research and modelling collaborations with partners worldwide



burnet.edu.au/partnerwithus

Australia (head office)
85 Commercial Road
Melbourne, Victoria, 3004
phone + 61 3 9282 2111
email info@burnet.edu.au
ABN 49 007 349 984

 burnet.edu.au